ISPC iSpecimen Inc.
Research report · from SEC EDGAR · close 2026-07-31
executive summary
iSpecimen Inc. (ISPC) is a $2.7M company. Revenue is $1.9M (-79.2% y/y) at a -544% net margin. It is not yet profitable. Our health score is D (41/100). 3 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$1.9M
-79.2% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-14.66).
⚠Active dilution shelf
An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$2.8M
Operating cash flow
-$4.2M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-31 by stocktools.ai.